AstraZeneca Pty Ltd v GlaxoSmithKline Australia Pty Ltd

The case of AstraZeneca Pty Ltd v GlaxoSmithKline Australia Pty Ltd involved AstraZeneca, a pharmaceutical company, suing GlaxoSmithKline (GSK), another pharmaceutical company, for misleading conduct under the Australian Consumer Law (ACL). AstraZeneca alleged that GSK made false or misleading representations regarding the benefits of its product, Seretide, a combination therapy for asthma. GSK denied these allegations, asserting that its marketing and promotional activities for Seretide were truthful and not misleading.

The primary legal issue the court needed to decide was whether GSK’s promotional activities regarding Seretide constituted misleading conduct under section 53 of the ACL. This involved examining whether the representations made by GSK about Seretide were false or misleading and whether such conduct could deceive or mislead consumers. The court also had to consider the context in which these representations were made and whether they influenced the market or consumer behaviour.

In its reasoning, the court examined the evidence provided by both parties, including expert testimonies from medical professionals. The court found that GSK's promotional activities for Seretide did not constitute misleading conduct. It concluded that the representations made by GSK were supported by scientific evidence and were not misleading to consumers. The court highlighted that the promotional materials accurately reflected the benefits of Seretide as understood at the time, and there was no evidence that GSK intended to mislead consumers. Therefore, the court dismissed AstraZeneca’s claims.

The final orders of the court were that the application by AstraZeneca be dismissed and that AstraZeneca pay GSK's costs. This decision underscores the importance of scientific evidence in supporting promotional claims in the pharmaceutical industry and the high threshold required to establish misleading conduct under the ACL.